Intech Investment Management LLC Increases Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Intech Investment Management LLC increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 6.0% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 7,573 shares of the biopharmaceutical company’s stock after purchasing an additional 428 shares during the period. Intech Investment Management LLC’s holdings in Alnylam Pharmaceuticals were worth $1,782,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Regeneron Pharmaceuticals Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $1,045,822,000. Geode Capital Management LLC increased its holdings in Alnylam Pharmaceuticals by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock worth $589,209,000 after acquiring an additional 66,928 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Alnylam Pharmaceuticals by 5.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 513,962 shares of the biopharmaceutical company’s stock valued at $120,940,000 after purchasing an additional 26,614 shares during the period. Eagle Asset Management Inc. grew its position in shares of Alnylam Pharmaceuticals by 25.7% during the 3rd quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock valued at $85,889,000 after purchasing an additional 63,385 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 3.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock worth $67,464,000 after purchasing an additional 8,462 shares during the period. Institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

ALNY has been the subject of several recent analyst reports. Morgan Stanley boosted their target price on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. JPMorgan Chase & Co. upped their price objective on shares of Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 11th. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Canaccord Genuity Group lifted their price objective on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. Finally, HC Wainwright raised their price target on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a research report on Monday, February 24th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $304.26.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the sale, the executive vice president now directly owns 12,881 shares in the company, valued at $3,240,344.36. This trade represents a 10.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Yvonne Greenstreet sold 1,213 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $309,521.21. Following the transaction, the chief executive officer now owns 81,526 shares in the company, valued at $20,802,989.42. This trade represents a 1.47 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Stock Up 0.1 %

NASDAQ ALNY opened at $253.60 on Friday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The stock has a market capitalization of $32.83 billion, a PE ratio of -116.87 and a beta of 0.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The business’s 50-day moving average is $256.25 and its 200 day moving average is $259.51.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.